 Tofacetinabcitrate is an oral Janus kinase 1 third inhibitor approved for rheumatoid arthritis, ulcerative colitis, and active psoriatic arthritis, and is increasingly being used off-label for dermatological conditions. A review of recent studies suggests that Tofacetinabcitrate shows strong efficacy for numerous dermatologic conditions, with randomized controlled trial data available for atopic dermatitis, alopecia areata, and plaque psoriasis, and case report and case series data available for other dermatologic conditions. However, further testing is needed to better characterize its efficacy and utility moving forward, as well as its safety and adverse effect profile. This article was authored by Carl Teckmeyer, Jeffrey Zhao, Nolan Jay Maloney, and others.